CIDP PBMC
About: CIDP PBMC samples are isolated from donors with clinically confirmed Chronic Inflammatory Demyelinating Polyneuropathy (CIPD). Ideal for studying autoimmune T and B cell responses, peripheral nerve inflammation, and mechanisms of demyelination.
| Lot # | Condition | Cell Count (M) | Race/Ethnicity | Age | Gender | Country of Collection | Medications | Vials | Price | Action |
|---|---|---|---|---|---|---|---|---|---|---|
| 73575 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 85 | Male |
IVig Q2W Eliquis 5 mg BID Metoprolol Zetia Crestor Tramadol PRN Furosemide Eliquis
|
1 | |||
| 73440 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 82 | Male |
Vitamins QD Amlodipine 5mg QD Gabapentin 300mg QD Losartan 50mg QD Xarelto 20mg QD
|
1 | |||
| 75281 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 85 | Male |
IVig Q3W Eliquis 5 mg BID Metoprolol QD Zetia QD Crestor QD Tramadol PRN Furosemide PRN
|
2 | |||
| 72939 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 10M | Caucasian | 69 | Male |
Vyndamax 61 mg QD
|
4 | |||
| 51866 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 5M | Caucasian | 60 | Female |
Synthroid 88 mcg QD IVIg 40 gm QD x 4 days Q6W Albuterol Inh PRN Potassium Chloride 20 mEq BID Pepcid 40 mg QD Nexium 40 mg QD Losartan 50 mg QD Advair Inh 1 puff BID HCTZ 25 mg QD Cellcept 1000 mg BID
|
4 | $891.00 | ||
| 52298 | Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) | 5M | Caucasian | 59 | Female | United States (US) |
IVIg QOW Fluticasone Nasal Spray Bupropion 150 mg QD Albuterol Inh PRN Fluoxetine 40 mg QD Pregabalin 100 mg Irbesartan 150 mg Simvastatin 10 mg Humalog Insulin Lantus Insulin Glucagon Ipratropium Nasal Spray Clonzepam
|
5 | $891.00 |
High-Quality CIDP PBMC for Research
CIDP PBMC products are sourced from donors clinically diagnosed with CIDP and processed under stringent conditions to support research. These cryopreserved peripheral blood mononuclear cells (PBMCs) enable studies on disease-specific immune dysregulation, T cell subsets, and cytokine production.
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed CIDP donors
- Available in cell counts ranging from 5 million to 2 billion
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Screen LeukoLot™ available prior to bulk orders
De-identified Donor Data
- Verified CIDP diagnosis
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional cidp-specific data available upon request
Applications
- Biomarker discovery and validation
- Drug screening and therapeutic development
- Immune pathway analysis in cidp pathophysiology
- Transcriptomic and proteomic profiling
Quality and Compliance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Shipping
CIDP PBMC samples are shipped on dry ice and available in custom aliquots. For international orders or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Frequently Asked Questions
1 Answer
Electronic medical records are an option to be included with the PBMC sample, as well as, flow cytometry and other phenotypic testing.
1 Answer
YES – we can often accommodate treatment-naive samples including various cancers, and you can specify immunosupression status or other requirements in the I/E criteria.
1 Answer
Self-reported infectious disease testing is always available and some of our products have additional testing.
1 Answer
HLA-typing is available for some of our PBMC products.
1 Answer
YES to both – Unique donors can be specified, and multiple vials from the same donor can be arranged. You can specify these requirements when ordering.
1 Answer
Healthy PBMCs achieve over 90% vialbity post-thaw. Although our disease-state PBMCs are processed with same stringent SOP, there is more variability depending upon disease. Learn more about our post thaw viability here. https://sanguinebio.com/pbmc-viability-quality-assurance/
Ask a Question
Need a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.